Simulations Plus Breaks Out Ahead of July Earnings

Simulations Plus, Inc. ( $SLP Simulations Plus, Inc. $18.24 ) is rallying into its mid-July report after back-to-back high-volume advances and technical breakouts. The stock’s momentum puts the next earnings print front and center as investors weigh whether bookings, renewals, and margin mix are improving enough to sustain the move.

The company builds modeling and simulation software used in model-informed drug development and provides scientific consulting to biopharma. After a choppy stretch for software revenue in late 2025 and early fiscal 2026, management pointed to healthier demand trends in the second quarter. That creates a straightforward test for whether this breakout has fundamental follow-through.

Breakout before July 14 earnings

In the latest session, shares jumped 11.4% on heavy trading volume and cleared both the 20- and 50-day moving averages, a pattern that often reflects improving sentiment. Recent market data also show the stock up 36.7% over one month and 50.5% over three months. The market value is around $368.5 million, with the stock changing hands near $18.

Earnings are scheduled for July 14. Consensus for that report sits near earnings of about 23 cents per share and revenue of about $20.9 million, which makes bookings color and margin commentary particularly important inputs for the market’s next move. If growth and mix hold near recent levels, the breakout could have support. If not, momentum can fade quickly in a small-cap name.

Business mix and bookings momentum

Management’s second-quarter update pointed to better demand across the portfolio. The company reported revenue of $24.3 million, up 8% year over year, with software at 60% of revenue and services at 40%. Executives highlighted strong software renewals and upsells, plus healthy services bookings that lifted backlog by about 18% during the quarter, according to the April 9 release.

The tone marked a change from the first quarter, when software revenue fell 17% year over year and total revenue declined 3%, even as services grew. That sequential improvement is what the market is trying to handicap now: are discovery and development solutions stabilizing, and can services growth continue without crimping margins?

What the market is weighing

Customer metrics offer a useful read-through on durability. On the latest earnings call, management cited 297 commercial clients, average revenue per client of about $124,000, and a quarterly renewal rate near 91%, with a trailing 12-month renewal rate around 87%. Leaders also noted that clinical operations software revenue declined sharply and now contributes a small single-digit percentage of the software mix, while discovery and development tools did the heavy lifting. Put together, the signals suggest core demand is holding up despite some client consolidation and site closures that pressured renewals last year. The integrated story around model-informed and AI-enabled workflows also came through in management’s commentary, which pointed to improving funding conditions at customers and more new-logo activity. Sustaining that renewal rate and backlog growth would go a long way toward supporting the stock’s recent optimism.

Risks to the breakout

This is a small-cap software-and-services name, and liquidity and valuation sensitivity are real risks. Momentum-driven moves can retrace fast if bookings slow, if renewal rates slip back toward the mid-80s, or if the mix tilts too far toward lower-margin services. Management also reduced its adjusted earnings outlook to $0.75 to $0.85 for fiscal 2026 due to a higher expected tax rate, which, while not an operating headwind, can weigh on sentiment. Execution risk remains around clinical operations and any lingering customer consolidation, and the stock’s recent gains leave less room for disappointment around July guidance or margin cadence. Investors may want to monitor trading volume in pullbacks as a gauge of whether new buyers are supporting higher levels.

What July earnings need to show

The near-term checklist is clear. First, confirmation that backlog and bookings are still expanding, ideally with software renewals in the high 80s to low 90s.

Second, software’s share of revenue holding around the company’s target range and services utilization staying healthy without compressing gross margin.

Third, commentary that customer funding conditions and new-logo adds remain constructive, and whether fiscal 2026 revenue guidance near $79 to $82 million is reaffirmed. If management also frames a path to stable margins in the back half, the technical breakout could transition into a fundamentals-backed move. If those pieces do not line up, the stock’s recent strength may prove fleeting. Either way, the July 14 report is likely to reset expectations for the second half and determine whether Simulations Plus keeps this spot on investors’ watch lists.